H.C. Wainwright raised the firm’s price target on Nektar (NKTR) to $135 from $120 and keeps a Buy rating on the shares after the company reported “encouraging” topline results from the 36-week induction phase of its Phase 2b REZOLVE-AA study of rezpeg in alopecia areata. Following the data, the firm is increasing its view of the odds of launch for rezpeg in AA to 25%, from 20%, and it projects the drug to generate risk-adjusted revenues of $59M in 2030, growing to $380M by 2035.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NKTR:
- Nektar price target raised to $115 from $98 at Oppenheimer
- Nektar Therapeutics Announces Phase 2b Trial Results
- Nektar’s rezpegaldesleukin shows proof of concept in Phase 2b alopecia trial
- Nektar to hold conference call on Phase 2b Rezpegaldesleukin results
- Coterra, Ovintiv, Nektar, Co-Diagnostics, Fluence: Trending by Analysts